Search

Your search keyword '"Takemoto, Hiroyoshi"' showing total 166 results
Start Over Author "Takemoto, Hiroyoshi"
166 results on '"Takemoto, Hiroyoshi"'

2. Phase II trial evaluating the long-term efficacy and peripheral sensory neuropathy of capecitabine plus oxaliplatin (XELOX) as adjuvant therapy in Japanese patients with operated stage III colon cancer

Author

Hata, Taishi, Uemura, Mamoru, Danno, Katsuki, Yoshioka, Shinichi, Matsuda, Chu, Kagawa, Yoshinori, Shingai, Tatsushi, Suzuki, Yozo, Tei, Mitsuyoshi, Tanida, Tsukasa, Komori, Takamichi, Okamura, Shu, Ota, Hirofumi, Takemoto, Hiroyoshi, Ogino, Takayuki, Miyoshi, Norikatsu, Yamamoto, Hirofumi, Murata, Kohei, Doki, Yuichiro, and Eguchi, Hidetoshi

Published
2024
Full Text
View/download PDF

9. Multicenter open-label randomized phase II study of second-line panitumumab and irinotecan with or without fluoropyrimidines in patients with KRAS wild-type metastatic colorectal cancer (PACIFIC study)

Author

Nagata, Naoki, Maeda, Hiromichi, Ishibashi, Keiichiro, Hirata, Keiji, Makiyama, Akitaka, Iwamoto, Shigeyoshi, Takemoto, Hiroyoshi, Imasato, Mitsunobu, Yoshida, Yoichiro, Munemoto, Yoshinori, Tanaka, Chihiro, Morita, Yoshitaka, Hotta, Yoshihiro, Toyofuku, Atsushi, Nagasaka, Takeshi, Morita, Satoshi, Sakamoto, Junichi, and Mishima, Hideyuki

Published
2019
Full Text
View/download PDF

10. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy (SENRI trial): A multicentre, randomised, controlled phase 3 trial

Author

Nishimura, Junichi, Satoh, Taroh, Fukunaga, Mutsumi, Takemoto, Hiroyoshi, Nakata, Ken, Ide, Yoshihito, Fukuzaki, Takayuki, Kudo, Toshihiro, Miyake, Yasuhiro, Yasui, Masayoshi, Morita, Shunji, Sakai, Daisuke, Uemura, Mamoru, Hata, Taishi, Takemasa, Ichiro, Mizushima, Tsunekazu, Ohno, Yuko, Yamamoto, Hirofumi, Sekimoto, Mitsugu, Nezu, Riichiro, Doki, Yuichiro, and Mori, Masaki

Published
2015
Full Text
View/download PDF

11. Combination antiemetic therapy with aprepitant/fosaprepitant in patients with colorectal cancer receiving oxaliplatin-based chemotherapy in the SENRI trial: analysis of risk factors for vomiting and nausea

Author

Takemoto, Hiroyoshi, Nishimura, Junichi, Komori, Takamichi, Kim, Ho Min, Ota, Hirofumi, Suzuki, Rei, Ikenaga, Masakazu, Ikeda, Masataka, Yamamoto, Hirofumi, Satoh, Taroh, Hata, Taishi, Takemasa, Ichiro, Mizushima, Tsunekazu, Doki, Yuichirou, Mori, Masaki, and Multicenter Clinical Study Group of Osaka, Colorectal Cancer Treatment Group (MCSGO)

Published
2017
Full Text
View/download PDF

12. A twice-daily or a three-times-daily tegafur-uracil and leucovorin calcium regimen as adjuvant therapy in patients with resected colorectal cancer: A phase III study.

Author

Iwamoto, Kazuya, primary, Hata, Taishi, additional, Miyake, Masakazu, additional, Ohue, Masayuki, additional, Shingai, Tatsushi, additional, Tei, Mitsuyoshi, additional, Takemoto, Hiroyoshi, additional, Ikenaga, Masakazu, additional, Fujie, Yujiro, additional, Miyoshi, Norikatsu, additional, Takahashi, Hidekazu, additional, Uemura, Mamoru, additional, Matsuda, Chu, additional, Mizushima, Tsunekazu, additional, Murata, Kohei, additional, Ohno, Yuko, additional, Doki, Yuichiro, additional, and Eguchi, Hidetoshi, additional

Published
2022
Full Text
View/download PDF

15. Administration Method of Adjuvant Tegafur-Uracil and Leucovorin Calcium in Patients with Resected Colorectal Cancer: A Phase III Study

Author

Hata, Taishi, primary, Hagihara, Kiyotaka, additional, Tsutsui, Anna, additional, Akamatsu, Hiroki, additional, Ohue, Masayuki, additional, Shingai, Tatsushi, additional, Tei, Mitsuyoshi, additional, Ikenaga, Masakazu, additional, Kim, Ho Min, additional, Osawa, Hideki, additional, Takemoto, Hiroyoshi, additional, Konishi, Ken, additional, Uemura, Mamoru, additional, Matsuda, Chu, additional, Mizushima, Tsunekazu, additional, Murata, Kohei, additional, Ohno, Yuko, additional, Doki, Yuichiro, additional, and Eguchi, Hidetoshi, additional

Published
2021
Full Text
View/download PDF

16. UGT1A1*6, 1A7*3, and 1A9*22 genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan

Author

Hazama, Shoichi, Mishima, Hideyuki, Tsunedomi, Ryouichi, Okuyama, Yusuke, Kato, Takeshi, Takahashi, Ken-ichi, Nozawa, Hiroshi, Ando, Hideaki, Kobayashi, Michiya, Takemoto, Hiroyoshi, Nagata, Naoki, Kanekiyo, Shinsuke, Inoue, Yuka, Hamamoto, Yoshihiko, Fujita, Yusuke, Hinoda, Yuji, Okayama, Naoko, Oba, Koji, Sakamoto, Jun-ichi, and Oka, Masaaki

Published
2013
Full Text
View/download PDF

20. Phase III Study on the Administration Method of Adjuvant UFT and Leucovorin Calcium in Patients with Resected Colorectal Cancer (Thrice-Daily versus Twice-Daily Regimen)

Author

Hata, Taishi, primary, Miyake, Masakazu, additional, Hagihara, Kiyotaka, additional, Tsutsui, Anna, additional, Akamatsu, Hiroki, additional, Ohue, Masayuki, additional, Shingai, Tatsushi, additional, Tei, Mitsuyoshi, additional, Ikenaga, Masakazu, additional, Kim, Ho Min, additional, Osawa, Hideki, additional, Takemoto, Hiroyoshi, additional, Konishi, Ken, additional, Uemura, Mamoru, additional, Matsuda, Chu, additional, Mizushima, Tsunekazu, additional, Murata, Kohei, additional, Ohno, Yuko, additional, Doki, Yuichiro, additional, Eguchi, Hidetoshi, additional, and Investigators Group, Clinical Study Group of the Osaka U, additional

Published
2020
Full Text
View/download PDF

31. CUBIC pathology: three-dimensional imaging for pathological diagnosis

Author

Nojima, Satoshi, primary, Susaki, Etsuo A., additional, Yoshida, Kyotaro, additional, Takemoto, Hiroyoshi, additional, Tsujimura, Naoto, additional, Iijima, Shohei, additional, Takachi, Ko, additional, Nakahara, Yujiro, additional, Tahara, Shinichiro, additional, Ohshima, Kenji, additional, Kurashige, Masako, additional, Hori, Yumiko, additional, Wada, Naoki, additional, Ikeda, Jun-ichiro, additional, Kumanogoh, Atsushi, additional, Morii, Eiichi, additional, and Ueda, Hiroki R., additional

Published
2017
Full Text
View/download PDF

32. The risk factors for vomiting and nausea in patients with oxaliplatin-based chemotherapy: Subgroup analysis of SENRI trial.

Author

Nishimura, Junichi, primary, Kudo, Toshihiro, additional, Takemoto, Hiroyoshi, additional, Komori, Takamichi, additional, Kim, Ho Min, additional, Ota, Hirofumi, additional, Suzuki, Rei, additional, Ikenaga, Masakazu, additional, Ikeda, Masataka, additional, Yamamoto, Hirofumi, additional, Satoh, Taroh, additional, Hata, Taishi, additional, Takemasa, Ichiro, additional, Mizushima, Tsunekazu, additional, Doki, Yuichiro, additional, and Mori, Masaki, additional

Published
2017
Full Text
View/download PDF

33. Learning curve for single‐incision laparoscopic totally extraperitoneal inguinal hernia repair.

Author

Wakasugi, Masaki, Nakahara, Yujiro, Hirota, Masaki, Matsumoto, Takashi, Kusu, Takashi, Takemoto, Hiroyoshi, Takachi, Ko, and Oshima, Satoshi

Subjects
INGUINAL hernia, TEACHERS' assistants, LEARNING by teaching
Abstract

Introduction: The learning curve for totally extraperitoneal repair (TEP) is longer and steeper than that for transabdominal preperitoneal repair (TAPP) due to the preperitoneal view to which the surgeon is not accustomed and the limited working space. The aim of this study was to clarify the learning curve for SILS‐TEP. Methods: A retrospective analysis of 80 consecutive patients with unilateral inguinal hernia was performed. All patients underwent elective SILS‐TEP performed by a single learning surgeon with a teaching assistant between July 2016 and March 2018 at Kinki Central Hospital. Results: The operative time decreased gradually after 20 cases and stabilized after 40 cases. The first 40 cases were categorized as the learning period group, and the remaining 40 cases were categorized as the experienced period group. More patients received antithrombotic therapy in the experienced period than in the learning period (P < 0.05). The median operative time was 107 and 60 min in the learning period and the experienced period, respectively (P < 0.05). There were no significant differences in blood loss peritoneal injury, conversion to a different procedure, postoperative hospital stay, complications, and recurrence between the two groups. No major complications or hernia recurrence were noted during follow‐up. Conclusions: The learning curve for SILS‐TEP might take 40 cases to reduce the operative time. SILS‐TEP can be performed safely by a learning surgeon with a teaching assistant. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

34. A resected case of medullary carcinoma of the ascending colon followed by infarction of the greater omentum mimicking anastomotic leakage

Author

Wakasugi, Masaki, primary, Kono, Hiroshi, additional, Yasuhara, Yumiko, additional, Tsujimura, Naoto, additional, Nakahara, Yujiro, additional, Matsumoto, Takashi, additional, Takemoto, Hiroyoshi, additional, Takachi, Ko, additional, Nishioka, Kiyonori, additional, Yoshida, Kyotaro, additional, and Oshima, Satoshi, additional

Published
2017
Full Text
View/download PDF

35. First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer

Author

Uemura, Mamoru, primary, Kim, Ho Min, additional, Hata, Tsuyoshi, additional, Sakata, Kazuya, additional, Okuyama, Masaki, additional, Takemoto, Hiroyoshi, additional, Fujii, Hitoshi, additional, Fukuzaki, Takayuki, additional, Morita, Tetsushi, additional, Hata, Taishi, additional, Takemasa, Ichiro, additional, Satoh, Taroh, additional, Mizushima, Tsunekazu, additional, Doki, Yuichiro, additional, and Mori, Maski, additional

Published
2016
Full Text
View/download PDF

36. Phase II study of irinotecan and bevacizumab plus alternate day S-1 as second-line treatment in patients with metastatic colorectal cancer.

Author

Tanaka, Chihiro, primary, Matsuda, Chu, additional, Kondo, Ken, additional, Tokunaga, Yukihiko, additional, Takahashi, Takao, additional, Kosugi, Chihiro, additional, Takemoto, Hiroyoshi, additional, Iwamoto, Shigeyoshi, additional, Oba, Koji, additional, Sakamoto, Junichi, additional, and Mishima, Hideyuki, additional

Published
2016
Full Text
View/download PDF

37. Efficacy of single‐incision laparoscopic totally extraperitoneal repair for irreducible or incarcerated inguinal hernia.

Author

Wakasugi, Masaki, Nakahara, Yujiro, Hirota, Masaki, Matsumoto, Takashi, Takemoto, Hiroyoshi, Takachi, Ko, Nishioka, Kiyonori, and Oshima, Satoshi

Subjects
INGUINAL hernia, SURGICAL emergencies, HERNIA, ILEUM
Abstract

Introduction: The aim of this study was to evaluate the efficacy of single‐incision laparoscopic surgery for totally extraperitoneal repair (SILS‐TEP) of irreducible inguinal hernias and incarcerated inguinal hernias. Methods: We performed a retrospective analysis of 194 patients, including 16 with irreducible or incarcerated hernia, who had undergone SILS‐TEP from May 2016 to December 2017 at Kinki Central Hospital. The outcomes of patients with irreducible or incarcerated hernia and those with reducible hernia were compared. For irreducible or incarcerated hernia, laparoscopic exploration with hernia reduction through an intraumbilical incision was performed. If no bowel resection was needed, one‐stage SILS‐TEP was performed. If bowel resection was required, two‐stage SILS‐TEP was performed 2–3 months after the bowel resection. Results: Of the 16 patients, 8 had an irreducible hernia, and 8 had an incarcerated hernia. The eight patients with an incarcerated hernia underwent emergency surgery, and among these patients, two needed single‐incision laparoscopic partial resection of the ileum followed by two‐stage SILS‐TEP. Fourteen patients, excluding the two patients who required single‐incision laparoscopic partial resection of the ileum, underwent laparoscopic exploration with hernia reduction followed by one‐stage SILS‐TEP. Among these 14 patients, one with an irreducible hernia required conversion to Kugel patch repair. The operative outcomes were generally comparable between the two groups. However, the operative time was longer for unilateral hernia, and more seromas were seen in the irreducible or incarcerated group. No other major complications or cases of hernia recurrence were noted in this study. Conclusions: SILS‐TEP, which offers good cosmetic results, can be safely performed for irreducible or incarcerated inguinal hernia. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

39. Neoadjuvant Chemotherapy Capecitabine and Oxaliplatin (XELOX) Combined with Bevacizumab for High-Risk Localized Rectal Cancer

Author

Takemoto Hiroyoshi, Fukunaga Mutsumi, Murata Kouhei, Nezu Riichirou, Kato Takeshi, Mori Masaki, Ikenaga Kazumasa, Sekimoto Mistugu, Tamagawa Hiroshi, Hata Taishi, Mizushima Tsunekazu, Kim Ho, Yamamoto Hirofumi, Ohue Masayuki, Doki Yuichiro, Fujie Yuichiro, Takemasa Ichirou, Ikeda Masataka, Hasegawa Junichi, Noura Shingo, Nishimura Junichi, and Miyake Yasuhiro

Subjects
Oncology, Chemotherapy, medicine.medical_specialty, Bevacizumab, Colorectal cancer, business.industry, medicine.medical_treatment, Hematology, medicine.disease, Oxaliplatin, Capecitabine, Internal medicine, Rectal carcinoma, medicine, business, medicine.drug
Published
2014
Full Text
View/download PDF

40. UGT1A1*6,1A7*3, and1A9*22genotypes predict severe neutropenia in FOLFIRI-treated metastatic colorectal cancer in two prospective studies in Japan

Author

Hazama, Shoichi, primary, Mishima, Hideyuki, additional, Tsunedomi, Ryouichi, additional, Okuyama, Yusuke, additional, Kato, Takeshi, additional, Takahashi, Ken-ichi, additional, Nozawa, Hiroshi, additional, Ando, Hideaki, additional, Kobayashi, Michiya, additional, Takemoto, Hiroyoshi, additional, Nagata, Naoki, additional, Kanekiyo, Shinsuke, additional, Inoue, Yuka, additional, Hamamoto, Yoshihiko, additional, Fujita, Yusuke, additional, Hinoda, Yuji, additional, Okayama, Naoko, additional, Oba, Koji, additional, Sakamoto, Jun-ichi, additional, and Oka, Masaaki, additional

Published
2013
Full Text
View/download PDF

41. A Phase II Study of XELOX and Cetuximab as First-Line Therapy in Patients With KRAS Wild Type Metastatic Colorectal Cancer (FLEET2 Study).

Author

Shoichi Hazama, Hiromichi Maeda, Shigeyoshi Iwamoto, Ho Min Kim, Hiroyoshi Takemoto, Kenji Kobayashi, Junichi Sakamoto, Naoki Nagata, Koji Oba, Hideyuki Mishima, Hazama, Shoichi, Maeda, Hiromichi, Iwamoto, Shigeyoshi, Kim, Ho Min, Takemoto, Hiroyoshi, Kobayashi, Kenji, Sakamoto, Junichi, Nagata, Naoki, Oba, Koji, and Mishima, Hideyuki

Published
2016
Full Text
View/download PDF

42. TJ-107 for the prevention of oxaliplatin-induced peripheral neuropathy: Results of a phase II randomized placebo-controlled clinical trial.

Author

Kono, Toru, primary, Hata, Taishi, additional, Munemoto, Yoshinori, additional, Matsui, Takanori, additional, Kojima, Hiroshi, additional, Takemoto, Hiroyoshi, additional, Fukunaga, Mutsumi, additional, Shimada, Mitsuo, additional, Nagata, Naoki, additional, Morita, Satoshi, additional, Sakamoto, Junichi, additional, and Mishima, Hideyuki, additional

Published
2012
Full Text
View/download PDF

43. Abstract 4134: Exploration for possible predictive biomarkers for individual response to mFOLFOX6 in colorectal cancer patients

Author

Suzuki, Okihide, primary, Murata, Kohei, additional, Fukunaga, Mutsumi, additional, Takemoto, Hiroyoshi, additional, Ohue, Masayuki, additional, Ikeda, Rikuko, additional, Wada, Satoru, additional, Eguchi, Hidetaka, additional, Tomita, Naohiro, additional, Watanabe, Masahiko, additional, Ishida, Hideyuki, additional, and Nishiyama, Masahiko, additional

Published
2011
Full Text
View/download PDF

45. A Case Report of Anal Canal Effectively Treated with Combined Radiation and Chemotherapy

Author

ISHIDA, Hideyuki, primary, TATSUTA, Masayuki, additional, FURUKAWA, Hiroshi, additional, IMAMURA, Hiroshi, additional, NAKAYAMA, Takahiro, additional, SHIMIZU, Junzo, additional, TAKEMOTO, Hiroyoshi, additional, KISHI, Kentaro, additional, KATO, Hitoshi, additional, YAMAMOTO, Kazuyoshi, additional, FUJISHIMA, Makoto, additional, and KAWASAKI, Takatoshi, additional

Published
2003
Full Text
View/download PDF

47. Correlation of Beta-Catenin and Cyclin D1 Expression in Colon Cancers

Author

Utsunomiya, Takehiro, primary, Doki, Yuichiro, additional, Takemoto, Hiroyoshi, additional, Shiozaki, Hitoshi, additional, Yano, Masahiko, additional, Sekimoto, Mitsugu, additional, Tamura, Shigeyuki, additional, Yasuda, Takushi, additional, Fujiwara, Yoshiyuki, additional, and Monden, Morito, additional

Published
2001
Full Text
View/download PDF

48. A Phase II Study of Combined Chemotherapy with 5-Week Cycles of S-1 and CPT-11 plus Bevacizumab in Patients with Metastatic Colon Cancer.

Author

Mizushima, Tsunekazu, Ide, Yoshito, Murata, Kohei, Ohashi, Ichiro, Yasumasa, Keigo, Fukunaga, Mutsumi, Takemoto, Hiroyoshi, Tamagawa, Hiroshi, Hasegawa, Junichi, Hata, Taishi, Takemasa, Ichiro, Ikeda, Masataka, Yamamoto, Hirofumi, Sekimoto, Mitsugu, Nezu, Riichiro, Doki, Yuichiro, and Mori, Masaki

Subjects
BEVACIZUMAB, IRINOTECAN, ACADEMIC medical centers, ANTINEOPLASTIC agents, BLOOD testing, COMBINATION drug therapy, COLON tumors, CONFIDENCE intervals, EPIDEMIOLOGY, FLUOROURACIL, METASTASIS, HEALTH outcome assessment, RESEARCH funding, SAFETY, SURVIVAL, DATA analysis, TREATMENT effectiveness, DATA analysis software, DESCRIPTIVE statistics, KAPLAN-Meier estimator, THERAPEUTICS
Abstract

Objective: Combined chemotherapy with S-1 and irinotecan (IRIS) for metastatic colorectal cancer has been reported to be effective and safe. However, there are only a few studies on the effects of adding bevacizumab to IRIS. We conducted a clinical study to evaluate the efficacy and safety of IRIS plus bevacizumab as first-line therapy for metastatic colorectal cancer. Methods: Forty metastatic colorectal cancer patients were enrolled in this phase II study. All patients received irinotecan (80 mg/m2) and bevacizumab (7 mg/kg) on days 1 and 15 and S-1 (40-60 mg twice daily) on days 1-21 of a 5-week repeated cycle. Results: The response rate was 47.4% [95% confidence interval (CI) 31.5-63.2], progression-free survival was 11.9 months (95% CI 9.4-16.8), and overall survival was 23.4 months (95% CI 19.0-inf). The only grade 3 hematological toxicity was neutropenia (16%) and the incidences of grade 3 nonhematological toxicity were low at <10%, other than diarrhea (10.9%). Conclusion: In this clinical study, we revealed IRIS plus bevacizumab to be a promising first-line regimen for metastatic colorectal cancer with a low incidence of serious toxicities, in which favorable response rates and extension of survival time can be expected. © 2013 S. Karger AG, Basel [ABSTRACT FROM AUTHOR]

Published
2013
Full Text
View/download PDF

49. [A Case of Concentrated Ascites Reinfusion Therapy(CART)for Abundant Refractory Ascites in Cecal Cancer with Peritoneal Dissemination Followed by the Readministration of Chemotherapy].

Author

Maemura K, Urakawa S, Kato J, Kidogami S, Fukata T, Nishida H, Ohigashi H, Takemoto H, and Fukuzaki T

Subjects
Male, Humans, Aged, Ascites etiology, Ascites therapy, Quality of Life, Peritoneum, Cecal Neoplasms complications, Cecal Neoplasms drug therapy, Cecal Neoplasms surgery, Liver Neoplasms drug therapy
Abstract

A 66-year-old man underwent laparoscopic ileocecal resection for cecal cancer with liver metastasis(cT3N1M1a, cStage Ⅳa). One month later, combination chemotherapy with capecitabine, oxaliplatin, and bevacizumab was administered for liver metastasis. However, during the treatment, peritoneal dissemination and abundant diuretic-resistant ascites was revealed, resulting in poor dietary intake. One year and 11 months after the surgery, the chemotherapy was interrupted and cell-free and concentrated ascites reinfusion therapy(CART)was undergone as palliative care. The initial volume of retrieved ascites was 6,500 mL, and the volume was increased gradually to a maximum of 14,020 mL without hemodynamic instability. Totally CART was administered 10 times during 7 months without any complications: mean volume of retrieved ascites; 9,780 mL/unit, the interval between therapies; 2-3 weeks. Serum albumin level did not decrease since CART administration. His oral intake and daily activities were improved by CART. These clinical outcomes contributed to the readministration of chemotherapy. We present a recent case of safe and periodical CART for abundant refractory ascites in cecal cancer with peritoneal dissemination, resulting in the improvement of QOL and the readministration of chemotherapy.

Published
2024

50. [A Case of Palliative Laparoscopic Surgery in an Older Woman with Advanced Gastric Cancer and a Large Hiatal Hernia].

Author

Kidogami S, Urakawa S, Fukata T, Nishida H, Takemoto H, Ohigashi H, and Fukuzaki T

Subjects
Aged, 80 and over, Female, Humans, Diaphragm pathology, Neoplasm Recurrence, Local surgery, Hernia, Hiatal surgery, Laparoscopy methods, Stomach Neoplasms surgery, Stomach Neoplasms pathology
Abstract

A 94-year-old woman presented with anorexia, persisting for several months, and marked anemia. An upper gastrointestinal endoscopy revealed type 3 advanced gastric cancer in the antrum. CT imaging indicated a large esophageal hiatus hernia and the elevation of the gastric fornix to the level of the bronchus. Wall thickening in the antrum, surrounded by increased fat tissue density, and swollen lymph nodes along the common hepatic artery, were detected. She was diagnosed with advanced gastric cancer(cT3N1M0, cStage Ⅲ)and a large hiatal hernia. A laparoscopic hiatal hernia repair and distal gastrectomy were performed. The cancer was exposed outside the serosa in the antrum, yet there was no indication of ascites, liver metastasis or peritoneal dissemination. The esophageal hiatus was sutured, and a distal gastrectomy(Billroth-Ⅱ reconstruction)was conducted. To avert hernia recurrence, sutures were applied to the posterior wall of the abdominal esophagus and the crus of the diaphragm, as well as the fornix of the remnant stomach and the diaphragm. Her postoperative course was uneventful, and she was discharged on POD13. There were no instances of gastric cancer recurrence or hiatal hernia 7 months post-operation.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results